Karachi: Liven Pharma Limited, a notable entity within the pharmaceutical sector, has announced a series of share transactions carried out by its Executive Director, Kaashif Hussain Siddique. The disclosure, made under PSX Regulation 5.6.4., detailed the sale of shares by Siddique on April 17, 2026, as per the company's announcement on July 14, 2026.

Siddique executed a total of ten transactions, all involving the sale of shares at a rate of 42.71 per share. The cumulative effect of these transactions has resulted in a decrease in Siddique's shareholding, now totaling 49.03 million shares. This series of sales has adjusted his cumulative percentage ownership in the company to 43.32%.

According to information available from the Pakistan Stock Exchange (PSX), the transactions were conducted in the ready market, a common practice among executive directors seeking to manage their investment portfolios. Such transactions are routinely disclosed to ensure transparency and maintain shareholder confidence.

The designated market for these transactions, as reported, reflects the active trading environment in which Liven Pharma operates, with the company's shares being closely monitored by investors and analysts alike. The impact of these sales on the overall market perception of Liven Pharma will be observed in the coming weeks, as stakeholders assess the implications of Siddique's reduced holding in the company.